CSL 040
Alternative Names: CSL-040Latest Information Update: 27 Oct 2023
At a glance
- Originator CSL Behring
- Class Anti-inflammatories; Glycoproteins; Recombinant proteins
- Mechanism of Action Complement receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Reperfusion injury
Most Recent Events
- 27 Sep 2023 Phase-I clinical trials in Reperfusion injury (In volunteers) in Australia (IV) (NCT05937581)
- 10 Jul 2023 CSL Behring plans a phase I trial for Immunodeficiency-disorders in healthy volunteers in unknown location (IV) (NCT05937581)
- 18 Dec 2020 CSL 040 is available for licensing as of 18 Dec 2020. https://www.cslbehring.com/partnering